Marksans Pharma Ltd Quarterly Results
Q3 FY25-26 Results Summary
Revenue
The revenue stands at ₹754.43 crore, reflecting a quarter-on-quarter *(QoQ) increase of 4.72 per cent from ₹720.41 crore. This corresponds to a year-on-year *(YoY) growth of 10.64 per cent.
Operating Profit
Operating Profit stands at ₹160.74 crore, reflecting a quarter-on-quarter *(QoQ) increase of 11.25 per cent from ₹144.49 crore. This corresponds to a year-on-year *(YoY) growth of 15.83 per cent.
PBDT
PBDT stands at ₹174.96 crore, reflecting a quarter-on-quarter *(QoQ) increase of 9.17 per cent from ₹160.26 crore. This corresponds to a year-on-year *(YoY) growth of 6.72 per cent.
Profit Before Tax
Profit Before Tax stands at ₹150.63 crore, reflecting a quarter-on-quarter *(QoQ) increase of 12.97 per cent from ₹133.34 crore. This corresponds to a year-on-year *(YoY) growth of 5.15 per cent.
Net Profit
Net Profit stands at ₹113.69 crore, reflecting a quarter-on-quarter *(QoQ) increase of 14.68 per cent from ₹99.14 crore. This represents a 8.21 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Marksans Pharma Ltd Earnings
- YOY
- QOQ
Marksans Pharma Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Marksans Pharma Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Marksans Pharma Ltd Financial Reports
Marksans Pharma Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Marksans Pharma | -1.45% | 7.58% | 16.86% | 18.13% | 6.91% | -12.81% |
| Corona Remedies | -0.47% | -3.91% | 3.30% | 15.06% | 13.57% | 13.57% |
| Strides Pharma | -0.27% | 7.24% | 13.69% | 34.58% | 31.29% | 61.04% |
| Viyash Scientific | -2.73% | -0.34% | 10.33% | 1.70% | 1.25% | 37.64% |
| P & G Health Ltd | -1.08% | 1.16% | 6.16% | -5.07% | -16.55% | 0.81% |
| Akums Drugs | -4.75% | -3.56% | 8.32% | 19.71% | 10.65% | -1.88% |
| Shilpa Medicare | -4.43% | 0.75% | 18.25% | 53.97% | 11.70% | 21.96% |
Company Info
Company Information
Chairman & Managing Director : Mark Saldanha
Company Sec. & Compli. Officer : Harshavardhan Panigrahi
Whole-time Director : Sandra Saldanha
Independent Director : Digant Mahesh Parikh
Whole-time Director : Varddhman Vikramaditya Jain
Independent Director : Abhinna Sundar Mohanty
Non Executive Director : Sunny Sharma
Independent Director : Shailaja Vardhan
Independent Director : Srinivas Mishra